The FDA filed civil money penalty complaints against four tobacco product manufacturers for manufacturing and selling e-liquids without marketing authorization.
- This is the first time the FDA has filed CMP complaints against tobacco product manufacturers to enforce FD&C Act’s premarket review requirements for new tobacco products
- As of Feb. 21, the FDA has filed CMP complaints against BAM Group doing business as VapEscape, Great American Vapes dba Great American Vapes, The Vapor Corner dba Vapor Corner, The Vapor Corner, and Vapor Corner, 13 Vapor Co. dba 13 Vapor
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.